<DOC>
	<DOCNO>NCT02995993</DOCNO>
	<brief_summary>Six patient Fabry disease recruit . Patients receive single dose 0.2 mg/kg recombinant human alpha-galactosidase A produce moss ( moss-aGal ) intravenous infusion . Patients hospitalized infusion least 24 hour end infusion . Treatment administer sequentially : patient show safety concern treatment day , treatment next patient commence follow day .</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics , Safety Moss-aGalactosidase A Patients With Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Patients Fabry disease evidence deficient αgalactosidase A ( αGal A ) activity αGal A gene mutation ( latter mandatory woman ) ; Treatment naïve Fabry patient Fabry patient pause enzyme replacement therapy Fabry disease due personal reason 3 month study entry ; Female male patient 18 &lt; =65 year ; At least one clinical manifestation Fabry disease include neuropathic pain , angiokeratoma , cornea verticillata , cardiomyopathy , hypo anhydrosis , abdominal pain , diarrhea , serum creatinine &gt; 1.0 mg/dL , proteinuria &gt; 300 mg/24 hour ; LysoGb3 concentration plasma upper limit normal ; Male patient female partner childbearing potential agree use medically acceptable method contraception ( e.g . condom , sexual abstinence , vasectomy ) , include rhythm method 30 day administration study medication ; Female patient childbearing potential must apply highly effective method birth control ( failure rate le 1 % per year use consistently correctly [ e.g . implant , injectables , combine oral contraceptive , intrauterine contraceptive device , sexual abstinence , vasectomized partner ] ) . The birth control method must apply least one monthly cycle prior first administration study medication 30 day administration study medication . Patient willing able ( opinion investigator ) understand comply procedure evaluation study ; Patient must willing legally able give write informed consent . Treatment enzyme replacement therapy Fabry disease within 3 month study entry ; Fabry patient pause enzyme replacement therapy Fabry disease due intolerability ; Patient positive antialphaGal A immunoglobulin G ( IgG ) Screening ; Participation clinical study medical device investigational medicinal product concurrently within 3 month study start ; Patient currently dialysis , expect begin dialysis study , receive kidney transplant , renal transplant wait list ; Patient unable comply protocol ( e.g . clinical relevant medical condition make implementation protocol difficult , unstable social situation , otherwise unlikely complete study ) , opinion investigator , otherwise unsuited study ; Known human immunodeficiency virus , hepatitis B surface antigen and/or hepatitis C infection ; Known allergy intolerabilities enzyme replacement therapy ; Hypersensitivity ( like anaphylactic reaction ) active substance excipients mossaGal ; Coadministration mossaGal chloroquine , amiodarone , benoquin gentamicin ; Breastfeeding pregnant woman ; Patients liver impairment ; Women sign cardiac fibrosis detectable echocardiography ; Other , Fabry diseaserelated severe illness ; Malignancies within past 5 year ; Liver transaminases &gt; =3 time upper Limit normal ; Alcohol and/or drug abuse ; Weight &gt; 100 kg ; Employees sponsor patient employee relative investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>